Erlotinib is a highly potent inhibitor of epidermal growth factor receptor tyrosine-kinase
activity that significantly prolongs overall survival in patients with non-small-cell lung cancer …

Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …

New drugs developed as anticancer therapy have focused on targeting molecules essential
to tumor growth and survival. In particular, protein kinases have emerged as key regulators …

Introduction: This phase 2 study was conducted to determine the efficacy and safety of
erlotinib alone and with bortezomib in patients with non-small cell lung cancer (NSCLC) …

The first-line treatment of advanced non-small-cell lung cancer (NSCLC) generally consists
of a maximum of six cycles of platinum-based doublet chemotherapy followed by …

Introduction BR. 21 demonstrated significant survival benefit for non-small cell lung cancer
patients receiving erlotinib compared with placebo. We undertook to characterize, by …

Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …

Lung cancer is the leading cause of cancer death worldwide. Despite the introduction of
more-effective chemotherapeutic agents, it appears that a survival plateau has been …

Purpose An intravenous (IV) erlotinib formulation has not been characterized in cancer
patients but may be useful in those with gastrointestinal abnormalities that impact on the …

19000 Background: Erlotinib significantly improved survival and quality of life while delaying
symptom progression compared with placebo in patients (pts) with relapsed NSCLC …